Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462
(800.88.CIGNA)

Amvuttra
(vutrisiran sodium)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		

Urgency:
☐ Standard ☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)

Medication requested:
☐ Amvuttra 25 mg/0.5 mL syringe
☐ other (please specify):

ICD10:

Directions for use: Dose: Quantity:
Duration of therapy: Frequency of therapy:
CPT Codes:

Is this a new start or continuation of therapy with the requested medication? If your patient has been taking samples, please pick "new start."
☐ New start
☐ Continuation of therapy

Where will this medication be obtained?
☐ Orsini
☐ US Bio
☐ Hospital Outpatient
☐ Retail pharmacy
☐ Other (please specify):
☐ Home Health / Home Infusion vendor
☐ Physician's office stock (billing on a medical claim form)

Facility and/or doctor dispensing and administering medication:
Facility Name: State: Tax ID#:
Address (City, State, Zip Code):

Where will this drug be administered?
☐ Patient's Home
☐ Hospital Outpatient
☐ Physician's Office
☐ Other (please specify):

NOTE: *Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting.*

Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? ☐ Yes ☐ No (provide medical necessity rationale):

Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? ☐ Yes ☐ No

What is your patient's diagnosis?

☐ Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis (ATTR-CM) Note: Variant Transthyretin Amyloidosis is also known as Hereditary Transthyretin Amyloidosis.
☐ Polyneuropathy of Hereditary Transthyretin–Mediated Amyloidosis (hATTR)
☐ Other (please specify):

Clinical Information:

****This drug REQUIRES supportive documentation for ALL answers, including genetic testing, chart notes, etc.****

(if polyneuropathy) Is documentation being provided that the patient has a transthyretin pathogenic variant as confirmed by genetic testing? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, medical test results, genetic test results, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. ☐ Yes ☐ No

(if polyneuropathy) Is documentation being provided that the patient has symptomatic polyneuropathy? Note: Examples of symptomatic polyneuropathy include reduced motor strength/coordination, and impaired sensation (for example, pain, temperature, vibration, touch). Examples of assessments for symptomatic disease include history and clinical exam, electromyography, or nerve conduction velocity testing. - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, medical test results, genetic test results, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. ☐ Yes ☐ No

(if polyneuropathy) Does the patient have a history of a liver transplant? ☐ Yes ☐ No

(if polyneuropathy) Is the requested medication prescribed by (or in consultation with) a neurologist, geneticist, or a physician who specializes in the treatment of amyloidosis? ☐ Yes ☐ No

(if cardiomyopathy) Is documentation being provided that the patient's diagnosis was confirmed by a technetium pyrophosphate scan (that is, a nuclear scintigraphy)? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, medical test results, genetic test results, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. ☐ Yes ☐ No

> (if cardiomyopathy, and no to previous question) Is documentation being provided that the patient's diagnosis has been confirmed by a tissue biopsy with confirmatory transthyretin (TTR) amyloid typing by mass spectrometry, immunoelectron microscopy, or immunohistochemistry? - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, medical test results, genetic test results, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. ☐ Yes ☐ No
>
> > (if cardiomyopathy, and no to previous question) Is documentation being provided that the patient's diagnosis was confirmed with genetic testing which, according to the prescriber, identified a transthyretin (TTR) pathogenic variant? Examples of TTR variants include Val122Ile variant and Thr60Ala variant. If the patient has wild-type amyloidosis, this is not a TTR pathogenic variant. - Please note: Documentation may include, but is not limited to, chart notes, laboratory tests, medical test results, genetic test results, claims records, and/or other information. Medical documentation specific to your response to this question must be attached to this case or your request could be denied. ☐ Yes ☐ No

(if cardiomyopathy) Has diagnostic cardiac imaging demonstrated cardiac involvement?
Notes: Examples of cardiac imaging include echocardiogram and cardiac magnetic imaging. Examples of cardiac involvement on imaging include increased thickness of the ventricular wall or interventricular septum ☐ Yes ☐ No

(if cardiomyopathy) Does the patient have heart failure? ☐ Yes ☐ No

> (if yes) Does the patient have New York Heart Association class IV disease? ☐ Yes ☐ No

(if cardiomyopathy) Is the requested medication prescribed by, or in consultation with, a cardiologist or a physician who specializes in the treatment of amyloidosis? ☐ Yes ☐ No

Is/Will this medication (be)ing used in combination with other medications indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis or transthyretin-mediated amyloidosis-cardiomyopathy (for example, Attruby [acoramidis tablets], Onpattro [patisiran intravenous infusion], Tegsedi [inotersen subcutaneous injection], Wainua [eplontersen subcutaneous injection], or a tafamidis product)? ☐ Yes ☐ No

Additional Pertinent Information: *Please provide any additional pertinent clinical information, including: if the patient is currently on the requested drug (with dates of use) and how they have been receiving it (for example: samples, out of pocket).*

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature:_____ **Date:**_____

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

V60125

 Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005